Here we summarize current knowledge on the structure, evolution and biological effects of AIB1 in the normal mammary gland and in ER positive and negative BC development and progression, providing insights into the rationale for targeting AIB1 in endocrine therapy resistant cancer. This evidence concerns the gene NCOA3 and breast cancer.